GLMD
- Galmed Pharmaceuticals Ltd.
()
Overview
Company Summary
Galmed Pharmaceuticals Ltd. (GLMD) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for the treatment of liver diseases. The company is particularly committed to addressing unmet medical needs in the field of non-alcoholic steatohepatitis (NASH) and fibrosis.
NASH is a chronic liver disease characterized by fat accumulation in the liver, leading to inflammation, fibrosis (scarring), and ultimately, cirrhosis, liver failure, or hepatocellular carcinoma. It is believed to be one of the leading causes of liver-related morbidity and mortality worldwide.
Galmed Pharmaceuticals aims to develop novel drugs that can effectively treat and improve the outcomes for patients suffering from NASH. The company's leading product candidate is Aramchol, a synthetic fatty-acid/bile-acid conjugate. Aramchol has shown promising results in preclinical and clinical studies, demonstrating potential benefits in reducing liver fat, inflammation, and fibrosis.
Galmed Pharmaceuticals is actively conducting clinical trials to evaluate the safety and efficacy of Aramchol in patients with NASH. These trials involve rigorous testing and analysis to assess how the drug impacts various disease-related parameters, including liver fat reduction, liver enzymes, fibrosis improvement, and overall patient health.
In addition to NASH, Galmed Pharmaceuticals is also exploring the potential of Aramchol in other liver-related disorders, such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).
Overall, Galmed Pharmaceuticals is dedicated to developing innovative therapeutics to address the significant medical challenge posed by NASH, with the ultimate goal of improving the lives of patients suffering from this debilitating liver disease.